Inna Uliyakina
University of Lisbon
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Inna Uliyakina.
Journal of Biological Chemistry | 2010
Rainer Schreiber; Inna Uliyakina; Patthara Kongsuphol; Richard Warth; Myriam Mirza; Joana Raquel Martins; Karl Kunzelmann
The calcium-activated chloride channel anoctamin1 (ANO1; TMEM16A) is fundamental for the function of epithelial organs. Mice lacking ANO1 expression exhibit transport defects and a pathology similar to cystic fibrosis. They also show a general defect of epithelial electrolyte transport. Here we analyzed expression of all ten members (ANO1–ANO10) in a broad range of murine tissues and detected predominant expression of ANO1, 6, 7, 8, 9, 10 in epithelial tissues, while ANO2, 3, 4, 5 are common in neuronal and muscle tissues. When expressed in Fisher Rat Thyroid (FTR) cells, all ANO proteins localized to the plasma membrane but only ANO1, 2, 6, and 7 produced Ca2+-activated Cl− conductance, as analyzed by ATP-induced iodide quenching of YFP fluorescence. In contrast ANO9 and ANO10 suppressed baseline Cl− conductance and coexpression of ANO9 with ANO1 inhibited ANO1 activity. Patch clamping of ANO-expressing FRT cells indicated that apart from ANO1 also ANO6 and 10 produced chloride currents, albeit with very different Ca2+ sensitivity and activation time. We conclude that each tissue expresses a set of anoctamins that form cell- and tissue-specific Ca2+-dependent Cl− channels.
PLOS ONE | 2012
Marisa Sousa; Maria de Fátima Correia Pimenta Servidoni; Adriana Mendes Vinagre; Anabela S. Ramalho; Luciana Cardoso Bonadia; Verónica Felício; Maria Ângela Gonçalves de Oliveira Ribeiro; Inna Uliyakina; Fernando A.L. Marson; Arthur Henrique Pezzo Kmit; Sílvia Regina Cardoso; José Dirceu Ribeiro; Carmen Silvia Bertuzzo; Lisete Sousa; Karl Kunzelmann; Antonio Fernando Ribeiro; Margarida D. Amaral
Background Cystic Fibrosis (CF) is caused by ∼1,900 mutations in the CF transmembrane conductance regulator (CFTR) gene encoding for a cAMP-regulated chloride (Cl−) channel expressed in several epithelia. Clinical features are dominated by respiratory symptoms, but there is variable organ involvement thus causing diagnostic dilemmas, especially for non-classic cases. Methodology/Principal Findings To further establish measurement of CFTR function as a sensitive and robust biomarker for diagnosis and prognosis of CF, we herein assessed cholinergic and cAMP-CFTR-mediated Cl− secretion in 524 freshly excised rectal biopsies from 118 individuals, including patients with confirmed CF clinical diagnosis (n = 51), individuals with clinical CF suspicion (n = 49) and age-matched non-CF controls (n = 18). Conclusive measurements were obtained for 96% of cases. Patients with “Classic CF”, presenting earlier onset of symptoms, pancreatic insufficiency, severe lung disease and low Shwachman-Kulczycki scores were found to lack CFTR-mediated Cl− secretion (<5%). Individuals with milder CF disease presented residual CFTR-mediated Cl− secretion (10–57%) and non-CF controls show CFTR-mediated Cl− secretion ≥30–35% and data evidenced good correlations with various clinical parameters. Finally, comparison of these values with those in “CF suspicion” individuals allowed to confirm CF in 16/49 individuals (33%) and exclude it in 28/49 (57%). Statistical discriminant analyses showed that colonic measurements of CFTR-mediated Cl− secretion are the best discriminator among Classic/Non-Classic CF and non-CF groups. Conclusions/Significance Determination of CFTR-mediated Cl− secretion in rectal biopsies is demonstrated here to be a sensitive, reproducible and robust predictive biomarker for the diagnosis and prognosis of CF. The method also has very high potential for (pre-)clinical trials of CFTR-modulator therapies.
Cell | 2013
Joana Almaça; Diana Faria; Marisa Sousa; Inna Uliyakina; Christian Conrad; Lalida Sirianant; Luka A. Clarke; José Paulo Martins; Miguel Santos; Jean-Karim Hériché; Wolfgang Huber; Rainer Schreiber; Rainer Pepperkok; Karl Kunzelmann; Margarida D. Amaral
Dysfunction of ENaC, the epithelial sodium channel that regulates salt and water reabsorption in epithelia, causes several human diseases, including cystic fibrosis (CF). To develop a global understanding of molecular regulators of ENaC traffic/function and to identify of candidate CF drug targets, we performed a large-scale screen combining high-content live-cell microscopy and siRNAs in human airway epithelial cells. Screening over 6,000 genes identified over 1,500 candidates, evenly divided between channel inhibitors and activators. Genes in the phosphatidylinositol pathway were enriched on the primary candidate list, and these, along with other ENaC activators, were examined further with secondary siRNA validation. Subsequent detailed investigation revealed ciliary neurotrophic factor receptor (CNTFR) as an ENaC modulator and showed that inhibition of (diacylglycerol kinase, iota) DGKι, a protein involved in PiP2 metabolism, downgrades ENaC activity, leading to normalization of both Na+ and fluid absorption in CF airways to non-CF levels in primary human lung cells from CF patients.
EBioMedicine | 2015
Nikhil T. Awatade; Inna Uliyakina; Carlos M. Farinha; Luka A. Clarke; Karina Mendes; Amparo Solé; Juan Pastor; Maria Margarida Ramos; Margarida D. Amaral
Background The best investigational drug to treat cystic fibrosis (CF) patients with the most common CF-causing mutation (F508del) is VX-809 (lumacaftor) which recently succeeded in Phase III clinical trial in combination with ivacaftor. This corrector rescues F508del-CFTR from its abnormal intracellular localization to the cell surface, a traffic defect shared by all Class II CFTR mutants. Our goal here is to test the efficacy of lumacaftor in other Class II mutants in primary human bronchial epithelial (HBE) cells derived from CF patients. Methods The effect of lumacaftor was investigated in primary HBE cells from non-CF and CF patients with F508del/F508del, A561E/A561E, N1303K/G542X, F508del/G542X and F508del/Y1092X genotypes by measurements of Forskolin plus Genistein-inducible equivalent short-circuit current (Ieq-SC-Fsk + Gen) in perfused open-circuit Ussing chambers. Efficacy of corrector C18 was also assessed on A561E/A561E and F508del/F508del cells. Results Our data indicate that A561E (when present in both alleles) responds positively to lumacaftor treatment at equivalent efficacy of F508del in primary HBE cells. Similarly, lumacaftor has a positive impact on Y1092X, but not on N1303K. Our data also show that cells with only one copy of F508del-CFTR respond less to VX-809. Moreover, there is great variability in lumacaftor responses among F508del-homozygous cells from different donors. Compound C18 failed to rescue A561E-CFTR but not in F508del-CFTR, thus plausibly it has a different mechanism of action distinct from lumacaftor. Conclusions CF patients with A561E (and likely also those with Y1029X) can potentially benefit from lumacaftor. Moreover, the methodology used here exemplifies how ex vivo approaches may apply personalized therapies to CF and possibly other respiratory diseases.
Scientific Reports | 2015
Hugo M. Botelho; Inna Uliyakina; Nikhil T. Awatade; Maria C. Proença; Christian Tischer; Lalida Sirianant; Karl Kunzelmann; Rainer Pepperkok; Margarida D. Amaral
Plasma membrane proteins are essential molecules in the cell which mediate interactions with the exterior milieu, thus representing key drug targets for present pharma. Not surprisingly, protein traffic disorders include a large range of diseases sharing the common mechanism of failure in the respective protein to reach the plasma membrane. However, specific therapies for these diseases are remarkably lacking. Herein, we report a robust platform for drug discovery applied to a paradigmatic genetic disorder affecting intracellular trafficking – Cystic Fibrosis. This platform includes (i) two original respiratory epithelial cellular models incorporating an inducible double-tagged traffic reporter; (ii) a plasma membrane protein traffic assay for high-throughput microscopy screening; and (iii) open-source image analysis software to quantify plasma membrane protein traffic. By allowing direct scoring of compounds rescuing the basic traffic defect, this platform enables an effective drug development pipeline, which can be promptly adapted to any traffic disorder-associated protein and leverage therapy development efforts.
Science Signaling | 2015
Cláudia Loureiro; Ana Margarida Matos; Ângela Dias-Alves; Joana Pereira; Inna Uliyakina; Patrícia Barros; Margarida D. Amaral; Paulo Matos
A molecular switch in a scaffolding protein enables a misfolded, but partially functional, cystic fibrosis protein to evade a quality control checkpoint. Treating cystic fibrosis by subverting quality control Cystic fibrosis is a genetic disorder that affects mostly lung function and is caused by mutations in the transmembrane protein CFTR (cystic fibrosis transmembrane conductance regulator) that regulates cellular fluid secretion and mucus production. Although most mutant versions of the protein retain some function, the cell recognizes the protein as defective and degrades it. The drug VX-809 (or lumacaftor) improves delivery of mutant CFTR to the cell surface, but the cell tags it for removal and degradation. Loureiro et al. found that triggering a conformational change in the scaffolding protein NHERF1 with Rac1 stimulation enables the interaction between NHERF1 and mutant CFTR, thereby preventing the interaction between mutant CFTR and the enzyme that tags it for degradation. Thus, the amount of the partially functional CFTR at the cell surface was higher in patient lung epithelial cells in culture. The findings may enhance the efficacy of VX-809 in cystic fibrosis patients. The peripheral protein quality control (PPQC) checkpoint removes improperly folded proteins from the plasma membrane through a mechanism involving the E3 ubiquitin ligase CHIP (carboxyl terminus of Hsc70 interacting protein). PPQC limits the efficacy of some cystic fibrosis (CF) drugs, such as VX-809, that improve trafficking to the plasma membrane of misfolded mutants of the CF transmembrane conductance regulator (CFTR), including F508del-CFTR, which retains partial functionality. We investigated the PPQC checkpoint in lung epithelial cells with F508del-CFTR that were exposed to VX-809. The conformation of the scaffold protein NHERF1 (Na+/H+ exchange regulatory factor 1) determined whether the PPQC recognized “rescued” F508del-CFTR (the portion that reached the cell surface in VX-809–treated cells). Activation of the cytoskeletal regulator Rac1 promoted an interaction between the actin-binding adaptor protein ezrin and NHERF1, triggering exposure of the second PDZ domain of NHERF1, which interacted with rescued F508del-CFTR. Because binding of F508del-CFTR to the second PDZ of NHERF1 precluded the recruitment of CHIP, the coexposure of airway cells to Rac1 activator nearly tripled the efficacy of VX-809. Interference with the NHERF1-ezrin interaction prevented the increase of efficacy of VX-809 by Rac1 activation, but the actin-binding domain of ezrin was not required for the increase in efficacy. Thus, rather than mainly directing anchoring of F508del-CFTR to the actin cytoskeleton, induction of ezrin activation by Rac1 signaling triggered a conformational change in NHERF1, which was then able to bind and stabilize misfolded CFTR at the plasma membrane. These insights into the cell surface stabilization of CFTR provide new targets to improve treatment of CF.
British Journal of Pharmacology | 2013
Yuemin Tian; Rainer Schreiber; Podchanart Wanitchakool; Patthara Kongsuphol; Marisa Sousa; Inna Uliyakina; Marta Palma; Diana Faria; Alexis Traynor-Kaplan; José I. Fragata; Margarida D. Amaral; Karl Kunzelmann
Ca2+‐dependent Cl− secretion (CaCC) in airways and other tissues is due to activation of the Cl− channel TMEM16A (anoctamin 1). Earlier studies suggested that Ca2+‐activated Cl− channels are regulated by membrane lipid inositol phosphates, and that 1‐O‐octyl‐2‐O‐butyryl‐myo‐inositol 3,4,5,6‐tetrakisphosphate octakis(propionoxymethyl) ester (INO‐4995) augments CaCC. Here we examined whether TMEM16A is the target for INO‐4995 and if the channel is regulated by inositol phosphates.
Pharmacology Research & Perspectives | 2015
Carlos M. Farinha; Marisa Sousa; Sara Canato; André Schmidt; Inna Uliyakina; Margarida D. Amaral
Cystic fibrosis (CF), the most common recessive autosomal disease among Caucasians, is caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR) protein. The most common mutation, F508del, leads to CFTR impaired plasma membrane trafficking. Therapies modulating CFTR basic defect are emerging, such as VX‐809, a corrector of F508del‐CFTR traffic which just succeeded in a Phase III clinical trial. We recently showed that VX‐809 is additive to two other correctors (VRT‐325 and compound 4a). Here, we aimed to determine whether the differential rescuing by these compounds results from cell‐specific factors or rather from distinct effects at the early biogenesis and/or processing. The rescuing efficiencies of the above three correctors were first compared in different cellular models (primary respiratory cells, cystic fibrosis bronchial epithelial and baby hamster kidney [BHK] cell lines) by functional approaches: micro‐Ussing chamber and iodide efflux. Next, biochemical methods (metabolic labeling, pulse‐chase and immunoprecipitation) were used to determine their impact on CFTR biogenesis / processing. Functional analyses revealed that VX‐809 has the greatest rescuing efficacy and that the relative efficiencies of the three compounds are essentially maintained in all three cellular models tested. Nevertheless, biochemical data show that VX‐809 significantly stabilizes F508del‐CFTR immature form, an effect that is not observed for C3 nor C4. VX‐809 and C3 also significantly increase accumulation of immature CFTR. Our data suggest that VX‐809 increases the stability of F508del‐CFTR immature form at an early phase of its biogenesis, thus explaining its increased efficacy when inducing its rescue.
bioRxiv | 2018
Inna Uliyakina; Ana Carina Da Paula; Sara C Afonso; Miguel J Lobo; Verónica Felício; Hugo M. Botelho; Carlos M. Farinha; Margarida D. Amaral
Background and Purpose: Cystic Fibrosis (CF) is caused by mutations in the CF Transmembrane conductance Regulator (CFTR), the only ABC transporter functioning as a channel. Unique to CFTR are two highly conformationally dynamic regions: the regulatory extension (RE) and regulatory insertion (RI). Removal of the latter rescues the trafficking defect of CFTR with F508del, the most common CF-causing mutation. We aimed here to assess the impact of RE removal (alone or with RI or genetic revertants) on F508del-CFTR traffic and how CFTR modulator drugs corrector VX-809/lumacaftor and potentiator VX-770/ivacaftor rescue these combined variants so as to gain insight into the mechanism of action (MoA) of these drugs. Experimental Approach. We generated ∆RE and ∆RI CFTR variants (with and without genetic revertants) by site-directed mutagenesis and used them to stably transfect BHK cell lines. We studied CFTR expression and stability by Western blotting and pulse-chase respectively, plasma membrane levels by cell surface biotinylation and channel activity by the iodide efflux technique. Key Results. Our data demonstrate that ∆RI significantly enhanced rescue of F508del-CFTR by VX-809. Thus, while the presence of the regulatory insertion seems to be precluding full rescue of F508del-CFTR processing by VX-809, this region appears essential to rescue its function by VX-770, thus suggesting some contradictory role in rescue of F508del-CFTR by these two modulators. Nevertheless, this negative impact of RI removal on VX-770-stimulated currents on F508del-CFTR can be compensated by deletion of the regulatory extension which also leads to the stabilization of this mutant. We thus propose that, despite both these regions being conformationally active, RI precludes F508del-CFTR processing while RE affects mostly its stability and channel opening. Supporting Information: Additional figures with supplementary data
Scientific Reports | 2018
Daniel Vigário Olivença; Inna Uliyakina; Luis L. Fonseca; Margarida D. Amaral; Eberhard O. Voit; Francisco R. Pinto
Phosphoinositides are signalling lipids that constitute a complex network regulating many cellular processes. We propose a computational model that accounts for all species of phosphoinositides in the plasma membrane of mammalian cells. The model replicates the steady-state of the pathway and most known dynamic phenomena. Sensitivity analysis demonstrates model robustness to alterations in the parameters. Model analysis suggest that the greatest contributor to phosphatidylinositol 4,5-biphosphate (PI(4,5)P2) production is a flux representing the direct transformation of PI into PI(4,5)P2, also responsible for the maintenance of this pool when phosphatidylinositol 4-phosphate (PI(4)P) is decreased. PI(5)P is also shown to be a significant source for PI(4,5)P2 production. The model was validated with siRNA screens that knocked down the expression of enzymes in the pathway. The screen monitored the activity of the epithelium sodium channel (ENaC), which is activated by PI(4,5)P2. While the model may deepen our understanding of other physiological processes involving phosphoinositides, we highlight therapeutic effects of ENaC modulation in Cystic Fibrosis (CF). The model suggests control strategies where the activities of the enzyme phosphoinositide 4-phosphate 5-kinase I (PIP5KI) or the PI4K + PIP5KI + DVL protein complex are decreased and cause an efficacious reduction in PI(4,5)P2 levels while avoiding undesirable alterations in other phosphoinositide pools.